David Lawrence

Dr. David Lawrence

Mental Health, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

29 April 2025 in Current Addiction Reports
Verified
Journal Article
Closed access
PDF file
EOEugene Osagie
Eugene Osagie
JHJacob Horton
Jacob Horton
David LawrenceDavid Lawrence
David Lawrence
GHGretchen Hermes
Gretchen Hermes
GGGabriela Garcia-Vassallo
Gabriela Garcia-Vassallo

1 August 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MMMichael F. Mayo-Smith
Michael F. Mayo-Smith
David LawrenceDavid Lawrence
David Lawrence

30 January 2026 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
SGSophie A. Goldman
Sophie A. Goldman
RWRiana Wurzburger
Riana Wurzburger
ESEleasa Sokolski
Eleasa Sokolski
David LawrenceDavid Lawrence
David Lawrence
PCPatricia A. Carney
Patricia A. Carney
PLPatricia Liu
Patricia Liu

9 May 2026 in Substance use & addiction journal
Verified
Journal Article
Closed access
David LawrenceDavid Lawrence
David Lawrence
PRPushpa V. Raja
Pushpa V. Raja
CYCristian D. Yanes
Cristian D. Yanes
JFJia Y. Fan
Jia Y. Fan
IMIsabella Morton
Isabella Morton
SGSonya E. Gabrielian
Sonya E. Gabrielian
Background: Medications for opioid use disorder (MOUD) are shown to improve quality of life while reducing risk for overdose and death among people with OUD. The Veterans Health Administration has supported numerous efforts to increase MOUD availability, but a treatment gap persists: among Veterans with OUD, half do not receive MOUD, and over 5000 died from overdose between 2016 and 2021. To improve MOUD adoption in a large VA health system, we developed a care model to identify and proactively engage Veterans with untreated OUD. Methods: The Virtual Outreach Low-Threshold MOUD care initiative (VOLT), a multi-faceted implementation bundle to support MOUD adoption, had 3 core elements: (1) an electronic health record-powered case-finder to identify individuals with untreated OUD and recent OUD-related clinical events (new OUD diagnosis, nonfatal opioid-involved overdose, acute care encounter for OUD, or referral to residential treatment for OUD), (2) case-finder result reconciliation by a physician champion, and (3) proactive tele-outreach to validated cases of untreated OUD by an MOUD prescriber. Results: The Case-Finder identified 526 encounters over a 2-year evaluation period. Most were either flagged for an inaccurate OUD diagnosis corrected by the physician champion (163, 31%), or validated as appropriate for tele-outreach (107, 20%). Of tele-outreach cases, 67 (63%) were contacted, and 37 (55%) were deemed MOUD-eligible. Of these, 28 (76%) initiated MOUD, all opting for buprenorphine. Retention on MOUD was 71% at 3 months and 57% at 6 months. The proportion of health system Veterans with OUD receiving MOUD increased from 44% pre- to 54% post-implementation. Conclusion: VOLT engaged Veterans with untreated OUD and recent OUD-related clinical events in buprenorphine care with high 3- and 6-month retention and was associated with a 10-percentage point increase in system-wide MOUD adoption. This novel care model may complement existing efforts to close the MOUD treatment gap.

23 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MCManuel Amando Celedon
Manuel Amando Celedon
AEAllan Enriquez
Allan Enriquez
JDJennifer Diaz
Jennifer Diaz
ZBZahir Basrai
Zahir Basrai
HAHemang Acharya
Hemang Acharya
CSComilla Sasson
Comilla Sasson
Background/Objectives: The VA Emergency Medicine Addiction Hotline (VEMAH) is a real-time telehealth addiction consult service for Veterans Health Administration (VHA) providers in acute-care settings. VEMAH launched in May 2023 across eight Veterans Integrated Service Network 22 (VISN 22) facilities, expanding to 17 total VHA sites over 3 years. Results: Over 38 months (May 7, 2023 through July 23, 2026), the service completed 2,154 encounters, including real-time e-consults, direct patient tele-care, care coordination, proactive tele-outreach, and provider education. The most common indications for consultation were opioid- and alcohol-related concerns. Pain-related concerns accounted for about 11% of all encounters. VEMAH providers focused on proactive outreach, substance use disorder (SUD) pharmacotherapy interventions, and coordinating care with local SUD services for ongoing treatment. Conclusions: We describe the feasibility of implementing and scaling a real-time telehealth addiction consult service across VHA acute care settings. A descriptive comparison of ED OSI dashboard trends before and after VEMAH implementation showed positive concurrent trends in naloxone and buprenorphine prescribing within VISN 22, though these observations are hypothesis-generating rather than confirmatory. These findings support VEMAH as a scalable model for extending addiction care access across VHA acute-care settings.